Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021
Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim
… ProQR Announces Second Quarter 2020 Operating and Financial … & CAMBRIDGE, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … said Daniel A. de Boer, Chief Executive Officer of ProQR. “We have continued to enroll patients in trials for …
… ProQR Announces First Quarter 2020 Operating and Financial … & CAMBRIDGE, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a … for the same period last year. Research and development (R&D) costs were €12.8 million for the quarter ended March 31, …